Background {#Sec1}
==========

The accomplishments of cardiovascular prevention have decreased the incidence of acute coronary syndromes (ACS) and have delayed the onset age of ACS. The progresses in the treatment of ACS (dual antithrombotic therapy and invasive strategy, e.g. the drug eluting stent) significantly lowers the mortality of ACS and lead to a swift growth in the portion of elderly patients. With the fast population ageing, the mean onset age of ACS patients rises stably in the last decades \[[@CR1]\]. Advanced age is one of the forceful prognosticators of mortality and morbidity of ACS. Age as a crucial prognostic marker is presented in the majority of ACS risk scores, including the Thrombolysis in Myocardial Infarction (TIMI) risk score and the Global Registry of Acute Coronary Events (GRACE) score \[[@CR2]\].

Frailty, one of the most important health problems in geriatrics, commonly exists in ACS patients, in part due to mutual risk factors. A frail phenotype representing decreased physiological reserve and increased vulnerability reflects better biological age, therefore, it may cause the heterogeneity in clinical consequences within the elderly patients \[[@CR3]\]. Frailty has become a substantial factor in assessment of several special medical situations and been embedded into clinical decision making, such as evaluation of surgical risk and cancer treatment. However, this has not yet become incorporated as part of routine management of ACS.

The well-defined pathways for the management of ACS, largely based on randomized controlled trial (RCT) evidence, may not be generalizable to elderly frail patients. Indeed, to date, there is no international guidelines as to how frail ACS patients should be treated. Previous studies have reported frailty was connected with higher mortality or adverse events in ACS patients with some inconsistent information. We therefore undertook a systematic review and meta-analysis to examine the significance of frailty on ACS prognosis, including mortality, cardiovascular events, major bleeding and readmission.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

The methods of this systematic review and meta-analysis were performed in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Statement \[[@CR4]\] (Additional file [1](#MOESM1){ref-type="media"}: Text S1). A comprehensive literature search was performed up to July 1, 2018. The language was restricted to English. The primary sources were the electronic databases of PubMed and Embase, using various combinations of Medical Subject Headings (MeSH) and non-MeSH terms: "Frailty" combined with "Myocardial Infarction", "Acute Coronary Syndrome" and "Heart Attacks". Additional file [1](#MOESM1){ref-type="media"}: Text S2 presents the full search strategy. All results were exported to EndNote for the removal of duplicates. We also screened reference lists of published reviews to identify additional relevant studies.

Study selection and data extraction {#Sec4}
-----------------------------------

The titles/abstracts and full texts were screened by two investigators (Qingyu Dou and Wen Wang) independently. Studies met following criteria were included: (1) performed a well-defined cohort design; (2) used frailty as a major exposure in elderly ACS patients; (3) elderly population with the age of 65 or greater (4) displayed hazard ratio (HR) or relative risk (RR) for outcomes with a 95% confidence interval (CI) or provided sufficient information to calculate these data. Exclusion criteria included: (1) case reports, reviews and conference abstracts; (2) insufficient parameters concerning main outcomes. (3) Using only one item (e.g. low gait speed) as a marker of frailty.

The related information and parameters from all included studies were extracted by two investigators including the first author's name, the year of publication, the place of study, the design of study, population, sample size, follow-up time, assessment methods of frailty, prevalence for frailty/prefrailty, and HR or RR of main outcomes with 95% CI. The main outcomes included all-cause mortality, cardiovascular events (re-infarction and stroke/TIA), composite outcome of death and cardiovascular events, major bleeding and readmission during follow-ups. When a cohort was represented by two or more studies, all available articles were included to make the most complete analyses. Discrepancies were addressed by discussion with a third author (Hui Wang).

Quality assessment {#Sec5}
------------------

Two authors independently assessed the quality of studies, and disagreements were re-evaluated by a third author. The Newcastlee-Ottawa Quality Assessment Scale \[[@CR5]\] was used to evaluate the quality of the literature. The scale assessed the selection of cohorts, comparability of cohorts and the quality of outcomes by 9 parameters. Scores range from 0 to 9. The quality of studies were graded as follows: good (≥ 8 stars); fair (5--7 stars); and poor (\< 5 stars).

Statistical analysis {#Sec6}
--------------------

We conducted analyses of adjusted and unadjusted estimates separately. We used relative risk (RR) or hazard risk (HR) as the effect measure for the association of frailty and adverse outcomes. HR or RR was pooled using random-effect generic inverse variance method. Statistical heterogeneity among studies were evaluated with chi-squared and I-squared statistics \[[@CR6]\]. We explored sources of heterogeneity using three pre-specified subgroup hypotheses: type of patients (frailty vs pre- frailty); type of ACS (ST-segment elevation myocardial infarction vs non-ST-segment elevation myocardial infarction); follow-up time (during hospital/within 1 month vs ≤ 1 year vs \> 1 year). Subgroup analyses were performed if there were at least two studies in each subgroup category. We detected publication bias using visually examining symmetry of funnel plots and Egger's tests \[[@CR7]\]. We performed a sensitivity analysis by omitting retrospective studies. All statistical tests will be performed with the STATA14.0 software. All statistical tests are two sided, *P* \< 0.05 is considered statistically significant.

Results {#Sec7}
=======

Search strategy and research characteristics {#Sec8}
--------------------------------------------

Overall, 1216 publications for possible inclusion were revealed by the initial systematic search of the databases. After the removal of duplicates, the remaining titles/abstracts were examined and irrelevant research were excluded, mainly because they were conference abstracts, reviews and case series. Then 24 left articles were carefully reviewed in full texts. Nine of them were excluded for different reasons. Fifteen studies \[[@CR8]--[@CR22]\] including 8554 patients were finally identified. No additional studies were found after manual inspection of the references. Figure [1](#Fig1){ref-type="fig"} showed the flow chart of literature search strategy and detailed reasons of exclusion. Fig. 1Flow chart of the selection process

Baseline characteristics of 15 studies \[[@CR8]--[@CR22]\] included are listed in Table [1](#Tab1){ref-type="table"}. The 15 included papers reported data from 13 individual cohort studies. Two papers reported data from one cohort investigating 1 month and 1 year mortality \[[@CR11], [@CR12]\]. Another 2 papers studied mortality of average 25 and 56.4 months after ACS from one cohort \[[@CR17], [@CR18]\]. There is one retrospective cohort study \[[@CR19]\] and the rest are prospective studies \[[@CR8]--[@CR18], [@CR20]--[@CR22]\]. The studies were conducted in the following countries: Spain, France, Sweden, Canada, Japan, Russia, China and multi-center of the world. All the studies enrolled both men and women with age older than 65 years. The median follow-up time varied from during admission to 56.4 months. Of 15 studies, 1 study enrolled STEMI patients; 4 study enrolled individuals with NSTEMI patients; 6 studies enrolled ACS patients; and 4 studies enrolled type 1 MI. Table 1Characteristics of included studies on association between frailty and clinical outcomesStudyStudy typeLocationType of ACSFrailty measureAgeSample Size (n)No.of MalesPrevalence (frailty,%)Prevalence (pre-frailty)Follow-up (mo)Ekerstad 2011ProspectiveSwedenNSTEMICSHA-CFS≥ 7530725748.50%N/A1Ekerstad 2014ProspectiveSwedenNSTEMICSHA-CFS≥ 7530725748.50%N/A12Graham 2013ProspectiveCanadaACSEFS≥ 6518312330.05%35.50%12Sanchis 2014ProspectiveSpainACSGreen scores≥ 6534219648.00%N/AMean 25 (31--72)Sanchis 2018ProspectiveSpainACSGreen scores≥ 6534219648.00%N/AMean 56.4Kang 2015ProspectiveChinaACSCSHA-CFS≥ 6535220343.20%N/A6.3Sujino 2015RetrospectiveJapanSTEMICSHA-CFS≥ 85623635.50%N/Ain-hospitalWhite 2016ProspectiveMulticentreUA/NSTEMIFried Frailty score≥ 65499626914.70%23.00%Mean  17.1 (10.4--24.4)Alonso 2016 aProspectiveSpaintype 1 MISHARE-FI≥7519011537.90%28.40%1Alonso 2016 bProspectiveSpaintype 1 MISHARE-FI≥7520212135.10%36.60%in-hospitalAlonso 2017ProspectiveSpaintype 1 MISHARE-FI≥7523413940.20%28.2%6Alonso 2018ProspectiveSpaintype 1 MISHARE-FI≥7528517138.20%29.80%12Kirill 2017ProspectiveRussiaACSComputer program of geriatric examinationelderly Senile633N/A35.50%N/A12Blanco 2017ProspectiveFranceACSEFS≥ 80236N/A20.8%28.8%Mean 15.7Alegre 2018ProspectiveSpainNSTEMIFRAIL scale≥ 8053232827.30%38.50%6*CSHA-CFS* Canadian Study of Health and Aging Clinical Frailty Scale; *EFS* Edmonton Frail Scale; *STEMI* ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; *ACS* acute coronary syndrome; *MI* myocardial infarction; *UA* unstable angina; *CSHA-CFS* Canadian Study of Health and Aging Clinical Frailty Scale; *SHARE-FI* Survey of Health, Ageing and Retirement in Europe Frailty Index; *N/A* not available

The assessment tool of frailty among these studies are as follows: 4 studies \[[@CR11], [@CR12], [@CR16], [@CR19]\] used Canadian Study of Health and Aging Clinical Frailty Scale (CSHA-CFS); 4 studies \[[@CR8], [@CR9], [@CR13], [@CR14]\] used Survey of Health, Ageing and Retirement in Europe Frailty Index (SHARE-FI) tool; 2 studies \[[@CR17], [@CR18]\] from the same cohort used Green Score; 2 studies \[[@CR10], [@CR15]\] used Edmonton Frail Scale (EFS); one \[[@CR20]\] used Fried Frailty score; and one \[[@CR21]\] used FRAIL scale. One last study \[[@CR22]\] determined frailty with the help of computer program "optimization of care in geriatrics, depending on the degree of frailty" on the basis of the specialized geriatric examination. All the 15 studies \[[@CR8]--[@CR22]\] reported the prevalence rate of frailty among participants, ranged from 4.7 to 53.2%. Eight studies \[[@CR8]--[@CR10], [@CR13]--[@CR15], [@CR20], [@CR21]\] reported the rate of pre-frailty ranged from 23.0 to 38.5%.

Risk of bias assessment {#Sec9}
-----------------------

Each study was considered to have adequate methodological quality based on the Newcastle-Ottawa Quality Assessment Scale. These 15 included studies \[[@CR8]--[@CR22]\] were of relatively high methodological quality with their scores ranging from 5 to 9 (mean score = 7.4) (Table [2](#Tab2){ref-type="table"}). Eight studies \[[@CR9], [@CR10], [@CR12]--[@CR15], [@CR17], [@CR20]\] were graded as good quality and the rest 7 studies \[[@CR8], [@CR11], [@CR16], [@CR18], [@CR19], [@CR21], [@CR22]\] were graded as fair. The representativeness of the exposed cohort, fully adjusted in the analysis and follow-up time were considered to be the most important indicators for methodological quality. Table 2Newcastle-Ottawa Score for the included studiesStudySelectionComparabilityOutcomeTotalEkerstad 20111111101017Ekerstad 20141111101118Graham 20131111111018Sanchis 20141111111108Sanchis 20181111101107Kang 20151111101017Sujino 20150111101005White 20161111111119Alonso 2016 a1111111018Alonso 2016 b1111101017Alonso 20171111111018Alonso 20181111111119Kirill 20171101001116Blanco 20170111111118Alegre 20180111101016

Frailty and adverse outcomes in patients with ACS {#Sec10}
-------------------------------------------------

### Frailty and mortality in ACS {#Sec11}

Using crude data, and taking robust patients as the control, frail group presented a significantly higher risk of mortality (RR = 3.16, 95%CI: 2.44--4.08, I^2^ = 36.0%, *P* = 0.11). After adjusted for potential confounders, compared to robustness, frailty (HR = 2.65; 95%CI: 1.81--3.89, I^2^ = 60.2%, *P* = 0.02) was characterized by a higher risk of mortality. The results were shown in Fig. [2](#Fig2){ref-type="fig"}a and Fig. [2](#Fig2){ref-type="fig"}b. Fig. 2Frailty and mortality in elderly patients with ACS: **a** Unadjusted all-cause mortality during the following-ups; **b** Adjusted all-cause mortality during the following-ups

### Frailty and the cardiovascular disease (CVD) risk in ACS {#Sec12}

Crude data from 7 studies \[[@CR8], [@CR9], [@CR12], [@CR14], [@CR20]--[@CR22]\] were used to examine the influence of frailty on any-type cardiovascular disease (CVD) risk (re-infarction and stroke/TIA) in ACS patients. The pooled RR demonstrated that ACS with frailty resulted in higher risk of any-type CVD risk during the follow-up (RR: 1.54; 95%CI: 1.32--1.79, I^2^ = 1.7%, *P* = 0.425) (Fig. [3](#Fig3){ref-type="fig"}a). When analyzing specific CVDs, compared to strong patients, frailty increased the risk of re-infarction of 68% (RR = 1.68, 95%CI: 1.35--2.09, *P* = 0.31, I^2^ = 15.5%) and tended to a 1.6-fold raised risk of stroke/TIA (RR = 1.60, 95%CI: 0.72--3.53, *P* = 0.547, I^2^ = 0%) (Table [3](#Tab3){ref-type="table"}). Fig. 3Frailty and any-type cardiovascular disease (CVD), major bleeding and readmission risk in elderly patients with ACS: **a** Unadjusted any-type CVD risk during the following-ups; (**b**) Unadjusted major bleeding risk during the following-ups; **c** Unadjusted readmission risk during the following-ups Table 3Unadjusted cardiovascular disease (CVD) risk in ACS during following-upsOutcomesNo. of StudiesEvents/TotalRR (95% CI)*P* valueI^2^FrailtyControlAny-type CVD Reinfarction7170/1031451/47941.68 (1.35, 2.09)0.3115.5% Stroke/TIA39/48161/39061.60 (0.72, 3.53)0.5470%Combined mortality with any type CVD Combined mortality or reinfarction265/20330/3163.39 (2.28, 5.04)0.8460% Combined mortality, reinfarction or stroke/TIA243/18016/3074.39 (2.56, 7.51)0.4080%*CVD* cardiovascular disease; *TIA* transient ischemic attack

When CVD was combined with all-cause mortality, 2 studies \[[@CR9], [@CR14]\] reported the composite outcome of death and re-infarction, and 2 studies \[[@CR9], [@CR13]\] reported the composite outcome of death and re-infarction or stroke/TIA. The corresponding unadjusted pooled RRs were 3.39 (95%CI: 2.28--5.04, *P* = 0.846, I^2^ = 0%) and 4.39 (95%CI: 2.56--7.51, *P* = 0.408, I^2^ = 0%) (Table [3](#Tab3){ref-type="table"}). Due to limited information of included studies, adjusted estimates of other outcomes were not performed.

### Frailty and major bleeding in ACS {#Sec13}

The major bleeding in ACS is defined as patients who had in-hospital intracranial hemorrhage, retroperitoneal bleed, hematocrit drop ≥12%, or need of red blood cells transfusion. Crude data from 6 studies \[[@CR8], [@CR9], [@CR14], [@CR16], [@CR20], [@CR21]\] were enrolled in the meta-analysis. We noted that frailty in ACS was associated with the significantly increased risk of major bleeding (RR = 1.51; 95%CI: 1.14--1.99; I^2^ = 13.2%, *P* = 0.33). (Fig. [3](#Fig3){ref-type="fig"}b).

### Frailty and readmission in ACS {#Sec14}

Six studies \[[@CR9], [@CR11], [@CR12], [@CR14], [@CR16], [@CR21]\] were included in the meta-analysis for the association of frailty in ACS with the risk of readmission. The incidence of readmission was significantly increased by 151% (RR = 1.51; 95%CI: 1.09--2.10, I^2^ = 85.2%, *P* = 0) in frail patients (Fig. [3](#Fig3){ref-type="fig"}c).

Subgroup analyses and publication bias {#Sec15}
--------------------------------------

Sufficient data were available to conduct subgroup analysis only for mortality. Compared with strong patients, pre-frailty significantly increased unadjusted risk of mortality at follow-up (RR = 1.86, 95%CI: 1.28--2.71, I^2^ = 40.1%). Similarly, pre-frailty displayed a significantly increased the risk of mortality after adjustment (HR =1.41; 95%CI: 1.19--1.66, I^2^ = 0%). The incidence of the mortality between frailty and pre-frailty revealed statistical significance before or after adjustment (test for interaction: *P* = 0.022 and *P* = 0.003 respectively). This finding illustrated the group of frailty showed higher mortality than pre-frailty group (Table [4](#Tab4){ref-type="table"}). Table 4Subgroup analyses of all-cause mortality according to the degree of frailty, follow-up time and type of ACSSubgroupNo. of StudiesUnadjusted\
RR (95%CI)I^2^P value of interactionNo. of StudiesAdjusted\
RR (95%CI)I^2^P value of interactionThe degree of frailty Frailty113.16 (2.44, 4.08)36.0%0.02272.65 (1.81, 3.89)60.2%0.003 Pre-frailty41.86 (1.28, 2.71)40.1%41.41 (1.19, 1.66)0%Follow-up time During admission/within 1 m33.63 (1.91, 6.90)0%0.9623.97 (1.65, 9.57)0%  ≤ 1 year73.44 (2.67, 4.44)0%33.80 (2.45, 5.90)0%0.18  \> 1 year23.06 (1.23, 7.65)58.8%32.13 (1.32, 3.44)73.3%Type of ACS STEMI22.13 (1.11, 4.09)0%0.4526.51 (2.01, 21.10)0%0.17 NSTEMI42.88 (1.86, 4.47)58.8%42.63 (1.51, 4.60)73.5%*STEMI* ST-segment elevation myocardial infarction; *NSTEMI* non-ST-segment elevation myocardial infarction; *ACS* acute coronary syndrome

Second, subgroup analyses were conducted according to follow-up time, which can be categorized by three periods, including short-term (during admission or within 30 days), mid-term (follow-up time ≤ 1 year) and long term (follow-up time \> 1 year). Overall, frail patients compared with the normal group experienced a similar unadjusted significantly increased risk for short (RR = 3.63; 95%CI: 1.91--6.90, I^2^ = 0.0%), mid (RR = 3.44; 95%CI: 2.67--4.44, I^2^ = 0.0%) and long-term (RR = 3.06; 95%CI: 1.23--7.65, I^2^ = 58.8%) mortality. After adjustment, frail patients still showed significantly increased risk for short (HR = 3.97; 95%CI: 1.65--9.57, I^2^ = 0.0%), mid (HR = 3.8; 95%CI: 2.45--5.90, I^2^ = 0.0%) and long-term (HR = 2.13; 95%CI: 1.32--3.44, I^2^ = 73.3%) mortality. The risks of mortality between subgroups did not show statistical significance (test for interaction: *P* \> 0.05). The risk of mortality at different time after ACS were all increased by frailty (Table [4](#Tab4){ref-type="table"}).

We also did the subgroup analyses to learn the connection between the different types of ACS and the mortality. STEMI and NSTEMI frail patients displayed significantly increased risk for mortality without adjustment (RR: 2.13, 95%CI: 1.11--4.09, I^2^ = 0.0% and RR: 2.88, 95%CI: 1.86--4.47, I^2^ = 58.8% respectively). When using the adjusted data, frailty was associated with significantly increased risk of mortality in STEMI (HR = 6.51, 95%CI: 2.01--21.10, I^2^ = 0%) and NSTEMI (HR = 2.63, 95%CI: 1.51--4.60, I^2^ = 73.5%) patients. No statistically significance was detected between subgroups (test for interaction: *P* \> 0.05). The results exhibited that frailty was a significant prognostic factor in either STEMI or NSTEMI, regardless of intra-hospital percutaneous coronary intervention (Table [4](#Tab4){ref-type="table"}).

No evidence of publication bias was found for the outcomes of unadjusted relative risk of all-cause mortality (Egger's test *P* = 0.123, Fig. [4](#Fig4){ref-type="fig"}). Due to limited numbers of included studies, we did not investigate publication bias for other outcomes. Fig. 4Funnel plots of studies included in the meta-analysis for unadjusted all-cause mortality

Sensitivity analysis by omitting Sujino's retrospective study did not show important changes in the pooled unadjusted (RR =3.17, 95% CI 2.42--4.17, I^2^ = 42.3%) and adjusted estimates (HR =2.65, 95% CI 1.77--3.98, I^2^ = 68.4%).

Discussion {#Sec16}
==========

In the present systematic review and meta-analysis, case series, conference abstracts or reviews, and studies used different exposure or outcome assessment were excluded. All the 15 included studies were of relatively high methodological quality. In the sensitivity analysis, the results were stable after the retrospective study by Sujino was removed. Our results demonstrated in elderly ACS patients, frailty significantly increased the all-cause mortality risk by 2.65-fold, any-type CVD risk by 1.54-fold, major bleeding risk by 1.51-fold and hospital readmissions risk by 1.51-fold.

A previous systematic review reported that the overall prevalence of frailty, in community-dwelling adults aged 65 and older, is on average 10.7%. Moreover, prevalence of frailty increases with age, reaching 15.7% in individuals aged 80 to 84 and 26.1% in those aged 85 or more \[[@CR23]\]. The proportion of frailty and pre-frailty in our meta-analysis were significantly higher than community population. Both ACS and frail patients had higher rates of common existed CVD risk factors, like hypertension, type 2 diabetes and lack of exercise. However, regardless of these possible mixed CVD risk factors, frailty itself brings about increased risk of CVD \[[@CR24]\]. The pathophysiologic mechanism of frailty, including elevated inflammatory state (interleukin-6 and C-reactive protein \[[@CR25]\]), higher markers of thrombosis (D-dimer \[[@CR25]\]) and endocrine unbalances (lower insulin-like growth factors − 1 \[[@CR26]\]) could act a part in the onset and outcome of ACS. Furthermore, frailty has accelerated biological aging modifications(e.g. higher oxidative stress levels \[[@CR27]\], impaired autophagy \[[@CR28]\] and shorter telomere length \[[@CR29]\] that further give impetus to the development and poor prognosis of ACS.

Frailty could impose obvious influence on the management of elderly ACS patients, especially on revascularization. Since the risk of operational complication rises in frail patients, a less invasive strategy may be preferred. Observational study shows primary percutaneous coronary intervention (PCI) was performed less frequently in patients with frailty compared with their non-frail counterparts \[[@CR30]\]. For STEMI patients, timely reperfusion in all patients with ischemia symptoms and persistent ST-segment elevation within 12 h, is the cornerstone of treatment. Studies have demonstrated performing PCI reduced in-hospital mortality, even in patients ≥80 years with frailty \[[@CR19], [@CR22]\]. Since our meta-analysis found frailty increased the risk of major bleeding, primary PCI is safer than fibrinolytic therapy especially in high risk elderly STEMI patients with frailty. However, frailty greatly increases all-cause mortality by 6.51-fold in STEMI patients in our study, which may reduce the ability to benefit from interventions. In these extremely frail STEMI patients with a high mortality despite intervention, the death risk should be fully informed and requires a shared decision by doctors and families. The decision not to accept interventional therapy is understandable and reasonable.

The role of an invasive strategy in frail NSTEMI patients is still worth exploring. An early invasive strategy was found to have more benefit in the elderly than younger patients, unless there were extensive and complicated comorbidities \[[@CR31], [@CR32]\]. Nowadays, there are studies aimed to judge whether the prognostic impact of PCI in NSTEMI differs across frailty status. The LONGEVO-SCA registry included unselected NSTEMI patients aged ≥80 years. The incidence of cardiac events was more common in patients managed conservatively after adjusting for confounding factors. However, this association was not significant in patients with established frailty criteria \[[@CR33]\]. In recent Nuñez's study \[[@CR34]\], a prospective observational study of 270 elderly patients hospitalized for NSTEMI, at a median follow-up of 4.4 years, in patients with Fried ≥3, PCI was associated with a significant reduction of risk of all-cause and cardiovascular-rehospitalizations without reducing all-cause mortality. In 2015 ESC guidelines for the management of NSTEMI, revascularization in elderly patients should be took into consideration after cautious weighing up benefits and risks, including comorbidities, frail state, predicted life expectancy, quality of life, and patient preferences \[[@CR35]\].

With regard to medical treatment, as bleeding risk increases with age, comorbidities, polypharmacy and declined renal function, elderly patients are at particular risk of bleeding. In addition to routine evaluation of bleeding risk (HAS-BLED bleeding score), based on our study, we also recommend that the frailty assessment be considered to tailor the individualized antithrombotic treatment for elderly patients. It is essential to reduce bleeding risk according to the degree of frailty; these include employing proper dosage of antithrombotic drugs, avoidance of a glycoprotein (GP) IIb/IIIa-inhibitor; adding a proton pump inhibitor; avoiding the use of non-steroid anti-inflammatory drugs and using radial access whenever possible \[[@CR36]\].

Our study found frailty increases both the risk of major bleeding and the risk of cardiovascular events. It is impossible to reduce the incidence of cardiovascular events by increasing the intensity of antiplatelet therapy. Frail patients are also less likely to take angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or β-blockers, since they are more likely to have adverse drug reactions from medical therapy. The frailty as a therapeutic goal intervened by non-pharmacological means is the future hotspot of research. The earlier stage of frailty is reversible and could be remedied. The non-pharmacological interventions (e.g. cardiac rehabilitation, physical exercise, and removing unnecessary medications may postpone and reduce the risk of CVD \[[@CR37], [@CR38]\]. A recent study showed patients with diabetes mellitus who have undergone PCI, cardiac rehabilitation participation was associated with significantly reduced all-cause mortality and composite end point of mortality, myocardial infarction, or revascularization \[[@CR39]\]. Meanwhile, nutritional supplement with 25--30 g of high-quality protein per meal have slowed or prevented sarcopenia, a manifestation of pre-frailty \[[@CR40]\]. In particular, physical activity interventions might play a pivotal role in the prevention of both CVD and frailty. More studies are required to confirm its function and establish standard exercise prescriptions.

Limitation {#Sec17}
----------

There are following limitations in our meta-analysis. First, even though we performed subgroup analysis according to type of ACS and follow-up time, there were not sufficient data to detect the statistical difference between subgroups. Second, the included criterion of our review was based on the age of 65 years or more. However, two studies just recruited participants older than 80 years and another study only included STEMI patients older than 85 years, which may result in the heterogeneity of our studies. Last, none of included studies in our meta-analysis reported results concerning quality of life. Future studies should use more patient-centered consequences such as activity of daily living (ADL) as primary outcome.

Conclusion {#Sec18}
==========

Our study suggests that in elderly ACS patients, frailty assessment should be integrated into the current existing management to better appraise the comprehensive prognosis risk. The identification of frailty help doctors to applicate appropriate management strategies including invasive therapy and antithrombotic medication, and help patients make properly informed choices. Further, the value of frailty as a therapeutic target should be given full attention. Currently, there is little evidence that frailty management could improve outcomes of elderly ACS patients. It is necessary to conduct more studies related the effect of the frailty intervention on elderly ACS prognosis in the future.
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ACS

:   acute coronary syndromes

ADL

:   activity of daily living

CI

:   confidence interval

CSHA-CFS

:   Canadian Study of Health and Aging Clinical Frailty Scale

CVD

:   cardiovascular disease

EFS

:   Edmonton Frail Scale

GP

:   glycoprotein

GRACE

:   Global Registry of Acute Coronary Events

HR

:   hazard ratio

MeSH

:   Medical Subject Headings

MI

:   myocardial infarction

MOOSE

:   Meta-analysis Of Observational Studies in Epidemiology

N/A

:   not available

NSTEMI

:   non-ST-segment elevation myocardial infarction

PCI

:   percutaneous coronary intervention

RCT

:   randomized controlled trial

RR

:   relative risk

SHARE-FI

:   Survey of Health, Ageing and Retirement in Europe Frailty Index

STEMI

:   ST-segment elevation myocardial infarction

TIA

:   transient ischemic attack

TIMI

:   Thrombolysis in Myocardial Infarction

UA

:   unstable angina
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